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Epidemiological evidence suggests that circulating 25-hydroxyvitamin D (25OHD) levels are inversely associated with hemoglobin
(Hb) levels and anemia risk. We evaluated whether vitamin D supplementation improves Hb levels and reduces anemia risk in
hypertensive patients. Two hundred patients with 25OHD levels <75 nmol/L who attended the Styrian Vitamin D Hypertension
Trial were included, of whom 188 completed the trial. Patients randomly received 2800 IU vitamin D3 daily or a matching placebo
for eight weeks. Initially, the prevalence of anemic status (Hb levels <12.5 g/dL) and deficient 25OHD levels (<30 nmol/L) was 6.5%
and 7.5%, respectively. All anemic patients had 25OHD levels >50 nmol/L.Themean (95% confidence interval) vitamin D effect on
Hb levels was 0.04 (−0.14 to 0.22) g/dL (𝑃 = 0.661). Moreover, vitamin D treatment did not influence anemic status significantly
(𝑃 > 0.999). Likewise, vitamin D had no significant effect on Hb levels in the subgroups of anemic patients or in patients with
initial 25OHD levels <30 nmol/L. In conclusion, a daily vitamin D supplement of 2800 IU for eight weeks did not improve Hb
levels or anemic status in hypertensive patients. Future trials should focus on anemic patients with deficient 25OHD levels (e.g.,
<30 nmol/L). This trial is registered with clinicaltrials.gov [NCT02136771].
1. Introduction
Anemia is a global health problem [1] and an independent
risk factor for increased morbidity and mortality in various
groups of patients, especially in patients with chronic diseases
and in the elderly [2]. Low levels of 25-hydroxyvitamin D
(25OHD) are also highly prevalent among these patients [3].
Recent epidemiological evidence suggests that circulating
25OHD is inversely associated with hemoglobin (Hb) levels
[4–15]. The risk of anemia is highest at deficient 25OHD
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2016, Article ID 6836402, 7 pages
http://dx.doi.org/10.1155/2016/6836402
2 International Journal of Endocrinology
levels (i.e., <30 nmol/L) and lowest at 25OHD levels of 50 to
125 nmol/L [4, 6, 15].
In chronic kidney disease (CKD) patients, some non-
randomized intervention studies could already show that
intravenous administration of activated vitamin D (1,25-




) is associated with an
increase in Hb levels within 12 months of treatment and a






a decreased weekly EPO dose of 50% [18]. Regarding Hb
levels, similar results have been obtained in hemodialy-
sis patients with oral alfacalcidol (1𝛼-vitamin D
3
) after 8
weeks [19] and also after 12 and 18 months of treatment
[20]. In hemodialysis patients, high-dose oral vitamin D
2
(50,000 IU monthly) was associated with dose-reductions
in erythropoiesis-stimulating agents (ESA), while Hb con-
centrations remained unchanged [21, 22]. In children with
CKD stage 5 and 25OHD levels <75 nmol/L, 12 weeks of
vitamin D
2





associated with a significantly reduced dose of ESA required
to treat the children [23]. In anemic patients with preserved
kidney function, however, one single intramuscular bolus
of 600,000 IU vitamin D
3
did not influence Hb levels [24].
Nevertheless, it is noteworthy that in general populations
the effect of high-dose bolus administration of vitamin D on
clinical outcomes has been questioned [25].
The purpose of the present study was to determine
the effect of a daily vitamin D
3
supplement on Hb levels
in a group of hypertensive patients with preserved kidney
function and inadequate 25OHD levels.
2. Methods
2.1. Study Design. This is a secondary analysis of the Styr-
ian Vitamin D Hypertension Trial of a postspecified end-
point. The study was a randomized, double-blind, placebo-
controlled, single-center trial which took place at the outpa-
tient clinic at the Division of Endocrinology andMetabolism,
Medical University of Graz, Austria. Major study results
have already been published elsewhere [26]. The study was
registered at EudraCT (number 2009-018125-70) and clinical-
trials.gov (NCT02136771). All study participants gave written
informed consent. The study was approved by the Ethics
Committee of the Medical University of Graz, Austria.
2.2. Participants. Two hundred study participants (106 men
and 94 women) were recruited from the clinics of the
Department of Cardiology and the Department of Inter-
nal Medicine, Division of Endocrinology and Metabolism,
Medical University of Graz, Austria, from June 2011 to
August 2014. Eligible study participants were adults aged 18
years or older with a serum 25OHD concentration below
75 nmol/L and arterial hypertension. Pregnant or lactating
women were excluded as well as patients with hypercalcemia
(serum calcium >2.65mmol/L), regular vitamin D intake
>880 IU per day during the last four weeks before the study,
estimated glomerular filtration rate (eGFR) <15mL/min per
1.73m2, drug intake as part of another clinical study, acute
coronary syndrome or cerebrovascular event in the previous
two weeks, 24-hour systolic BP >160mmHg or <120mmHg,
24-hour diastolic BP >100mmHg, change in hypertensive
treatment (drugs or lifestyle) in the previous four weeks or
planned changes in antihypertensive treatment during the
study, any disease with an estimated life expectancy of <1
year, any clinically significant acute disease requiring drug
treatment, and chemotherapy or radiation therapy.
2.3. Intervention. Eligible study participants were randomly
allocated to receive 2800 IU (70 𝜇g) cholecalciferol as seven
oily drops per day (Oleovit D3, Fresenius Kabi Austria, Graz,
Austria) or a matching placebo for eight weeks. The dose of
2,800 IU vitamin D per day was chosen because a rule of
thumb suggests that vitamin D supplementation of 1,000 IU
increases 25OHD levels by approximately 25 nmol/L [27].
Given that a commonly used normal range of 25OHD is 75
to 150 nmol/L [28] we conclude that a supplementation of
2,800 IU daily may be sufficient to increase the 25OHD level
of most study participants to target ranges without causing
supraphysiological 25OHD levels. One hundred patients
were assigned to the intervention group and 100 patients to
the control group. Randomization was performed by web-
based software (http://www.randomizer.at/) with a permuted
block randomization (block size of 10 and stratification
according to sex).
2.4. Endpoints. The primary outcome measures were Hb
levels and anemia. In accordance with earlier classifications
[4, 6, 29], Hb concentrations <12.5 g/dL were considered as
anemic, which corresponded to the average threshold value
of the World Health Organization gender-based definition
(<13.0 g/dL in men and <12.0 g/dL in women).
2.5. Biochemical Measurements. Blood sampling was per-
formed in the morning between 7 and 11 am after an
overnight fast. All blood samples were either measured at
least four hours after blood collection or immediately
stored at −20∘C until analysis. Measurement of 25OHD
was performed by chemiluminescence assay (IDS-iSYS 25-
hydroxyvitamin D assay; Immunodiagnostic Systems Ltd.,
Boldon, UK) on an IDS-iSYS multidiscipline automated ana-
lyzer. Lower and upper quantification limits were 17.5 nmol/L
and 312.5 nmol/L, respectively. All hematological parameters
were measured on a Sysmex® XE-5000 automated hematol-
ogy analyzer (Sysmex America, Inc., Mundelein, IL, USA).
eGFR was calculated using Modification of Diet in Renal
Disease [30].Themeasurements of other biochemical param-
eters have been described elsewhere [26]. In accordance
with published data [31, 32] we categorized 25OHD levels
<30 nmol/L as deficient, 30–49.9 nmol/L as insufficient, and
50 to 74.9 nmol/L as borderline.
2.6. Statistics. Categorical variables are reported as a percent-
age of observations. Normally distributed continuous data
are shown as means with standard deviation. We used the
Kolmogorov-Smirnov test to check normal data distribution.
Normal distribution was a consideration when probability
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Table 1: Baseline characteristics of the study groups.
Characteristics Vitamin D group Placebo group P value
(𝑛 = 100) (𝑛 = 100)
Females (%) 46 48 0.777
Age (years) 60.5 ± 10.9 59.7 ± 11.4 0.607
Anemic subjects1 (%) 9 4 0.152
BMI (kg/m2) 30.4 ± 4.4 30.4 ± 6.2 0.967
Active smoker (%) 19 14 0.341
Previous MI (%) 8 5 0.390
Previous stroke (%) 9 7 0.602
Diabetes mellitus (%) 32 41 0.186
25OHD (nmol/L) 54.5 ± 13.6 51.0 ± 14.2 0.073
PTH (pmol/L) 5.2 (4.2–6.5) 5.5 (4.2–7.0) 0.931
Phosphate (mg/dL) 2.9 ± 0.5 3.0 ± 0.5 0.085
Calcium (mmol/L) 2.37 ± 0.10 2.37 ± 0.11 0.989
Hemoglobin (g/dL) 14.4 ± 1.3 14.4 ± 1.4 0.665
Hematocrit (%) 41.1 ± 3.3 41.5 ± 3.4 0.329
Leukocyte counts (109/L) 5.9 (5.1–7.0) 6.0 (5.0–7.5) 0.817
Erythrocyte counts (1012/L) 4.8 ± 0.4 4.9 ± 0.4 0.237
MCV (𝜇m3) 86.1 ± 4.4 85.7 ± 4.0 0.457
MCH (pg Hb/red blood cell) 30.1 ± 1.9 29.8 ± 1.6 0.234
MCHC (g/L) 34.9 ± 1.0 34.7 ± 1.1 0.207
Platelets (109/L) 239 ± 64 232 ± 50 0.442
MPV (fl) 10.7 ± 1.0 10.7 ± 0.9 0.572
CRP (mg/L) 2.3 (1.13–3.8) 1.4 (0.9–3.4) 0.044
eGFR (mL/min/1.73m2) 80.0 ± 17.9 77.2 ± 17.9 0.272
Vitamin D supplement (%) 5 9 0.268
ACE-inhibitor (%) 25 38 0.048
AT II blocker (%) 33 31 0.762
Diuretic (%) 42 48 0.394
Beta-blocker (%) 44 49 0.478
Statin (%) 26 32 0.350
Calcium channel blocker (%) 27 25 0.747
1Hemoglobin <12.5 g/dL.
25OHD: 25-hydroxyvitamin D; ACE: angiotensin converting enzyme; AT: angiotensin; BMI: body mass index; CAD: coronary artery disease; CRP: C-
reactive protein; eGFR: estimated globular filtration rate; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular
hemoglobin concentration; MI: myocardial infarction; MPV: mean platelet volume; PTH: parathyroid hormone.
values were >0.05. Variables with a skewed distribution are
shown as medians with interquartile range. Change from
baseline data is shown as means and 95% confidence interval
(CI). We used the McNemar test and Fisher’s exact test,
respectively, to assess differences in anemic status within and
between groups. The unpaired 𝑡-test or chi-squared test was
used for group comparisons at baseline. Skewed variables
were normalized by logarithmic transformation before use
in parametric statistical analysis. ANCOVAwith adjustments
for baseline values was used to test for differences in the
outcome variables between the vitamin D and the placebo
group at the follow-up visit. We considered 𝑃 values <
0.05 (two-sided) as statistically significant. Analyses were
performed using SPSS version 21.0 (SPSS, Inc., Chicago, IL,
USA).
3. Results
Baseline characteristics of the study participants are shown in
Table 1. In both groups, mean Hb values were clearly above
the anemia threshold of 12.5 g/dL. At baseline, the proportion
of anemia in the vitamin D and placebo groups was 9.0% and
4.0%, respectively (𝑃 = 0.152).
Regarding 25OHD levels, 6.0% of the vitamin D group
and 9.0% of the placebo group had deficient levels. The
proportion of insufficient 25OHD levels was 27.0% and
36.0%, respectively. In the remaining 67.0% and 55.0%, the
vitamin D status was classified as borderline.
Of the 200 participants, 188 terminated the study as
planned. Table 2 shows the treatment results on biochemical
parameters.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































International Journal of Endocrinology 5
































Figure 1: Anemia proportion in participants of the Styrian Vitamin
D Hypertension Trial at baseline and study termination (by study
group). 𝑃 values indicated within study group results.
Circulating 25OHD increased on average by 35.4 nmo/L
(95% CI: 31.2 to 39.6 nmol/L) in the treatment group and
8.1 nmol/L (95% CI: 4.6 to 11.7 nmol/L) in the placebo group
(𝑃 < 0.001). There was no significant vitamin D effect on
Hb levels (Table 2). In both study groups, Hb levels remained
almost constant. Moreover, vitamin D treatment did not
influence anemic status significantly (𝑃 > 0.999). In detail,
the percentage of anemic subjects remained constant in the
vitamin D group (𝑃 > 0.999) and increased only slightly
in the placebo group (𝑃 > 0.999) (Figure 1). Vitamin D
treatment had no effect on other hematological parameters
(Table 2).
All anemic patients had initial 25OHD levels>50 nmol/L.
Vitamin D treatment had no effect on Hb levels and other
hematological parameters in anemic patients (see Table S1 in
Supplementary Material available online at http://dx.doi.org/
10.1155/2016/6836402). Moreover, there was no vitamin D
effect on Hb levels and other hematological parameters in
the group of subjects with initial 25OHD levels <30 nmol/L
(Table S2).
Therewas, however, a significant vitaminD effect on PTH
levels, with suppressed PTH levels in the vitamin D group
(Table 2). Vitamin D treatment did not influence serum
calcium and phosphate levels.
4. Discussion
This study showed that a daily vitamin D supplement of
2800 IU for 8 weeks had no effect on Hb levels or anemia risk
in hypertensive patients with 25OHD levels <75 nmol/L.
Our study has several strengths. First, this is a random-
ized, placebo-controlled trial. In addition, compared with
previous interventional studies we were able to include a
large number of patients. Next, we included only patients
with relatively low circulating 25OHD levels. Moreover,
the daily vitamin D dose was sufficient to increase in-study
25OHD levels on average clearly above 75 nmol/L.This value
is recommended by many endocrinologists and vitamin D
researchers as the lower target level for various clinical
outcomes [33, 34]. Our study also has some limitations. First,
the prevalence of anemic patients at baseline was low. Second,
the study duration of 8 weeks was relatively short, given that
the half-life of red blood cells in circulation is 3 months.
Third, we have no data on circulating levels of 1,25(OH)
2
D,
which is the active, hormonal form of vitamin D.
Generally, evidence is increasing that 1,25(OH)
2
D can
stimulate erythropoiesis in red blood cell precursor cells by
increasing EPO sensitivity. Furthermore, 1,25(OH)
2
D can
upregulate proliferation of hematopoietic progenitor cells
[35, 36]. Nevertheless, our findings with plain vitamin D
in patients with preserved kidney function do not support
the beneficial impact on Hb levels of earlier studies with
activated vitamin D in CKD patients [16, 17]. It is, however,
noteworthy that in CKD patients the prevalence of anemia
is high and circulating 1,25(OH)
2
D levels are low. Moreover,
a recent meta-analysis of randomized controlled trials has
demonstrated that, after administration of vitamin D or
activated vitamin D, the increase in circulating 1,25(OH)
2
D
tends to be much higher in CKD patients than in non-CKD
patients [37]. In our study, a vitamin D-induced increase in
circulating 1,25(OH)
2
D levels may have been blunted by the
suppressed PTH levels, and thismay have contributed, at least
in part, to the null effect on Hb levels.
In the present study, the prevalence of deficient 25OHD
levels was low. Moreover, it was a surprising finding that
all 13 anemic patients had initial 25OHD levels >50 nmol/L.
Generally, epidemiological evidence suggests that circulating
25OHD levels are inversely associated with Hb levels and
anemia risk [4, 6]. A recent meta-analysis of retrospective
observational studies showed that, compared with individ-
uals with adequate 25OHD levels, low 25OHD levels were
associatedwith an odds ratio for anemia of 2.25 (95%CI: 1.47–
3.44) [38].The cut-off for low 25OHD levels was 50 nmol/L in
5 out of the 7 included studies and 75 nmol/L in the remaining
2 studies. Only individuals without chronic diseases were
included in that meta-analysis. However, two large studies
in patients with cardiovascular disease [4, 6] indicate that
Hb levels are only significantly affected if circulating 25OHD
levels are in the deficiency range. Also of note is the fact that
observational studies have shown circulating 1,25(OH)
2
D to
be a better predictor of anemia than circulating 25OHD
[4, 5, 39]. Altogether, data indicate that especially anemic
patients with deficient 25OHD levels and low circulating
1,25(OH)
2
D levels may benefit from improved vitamin D
status.
5. Conclusions
In conclusion, our data demonstrate that a daily vitamin
D supplement of 2800 IU for 8 weeks does not increase
Hb levels in nonanemic hypertensive patients with 25OHD
levels <75 nmol/L. Future studies in this field should focus on
anemic individuals with deficient 25OHD levels.
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